Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099939 | 0.85 | ALDH1A1 (0.55) | KCNA5ALDH1A1KDM4ERCE1ACLY | |
| SCHEMBL1110334 | 0.85 | KCNA5 (0.46) | KCNA5ALDH1A1KDM4ERCE1ACLY | |
| SCHEMBL1110272 | 0.85 | KCNA5 (0.48) | KCNA5ALDH1A1KDM4EACLYMEN1 | |
| SCHEMBL1319403 | 0.84 | KCNA5 (0.61) | KCNA5ALDH1A1KDM4EACLYMEN1 | |
| SCHEMBL1110242 | 0.84 | KCNA5 (0.47) | KCNA5ALDH1A1KDM4EACLYMEN1 | |
| SCHEMBL1110519 | 0.83 | HPGD (0.58) | ALDH1A1KDM4ERCE1ACLYMEN1 | |
| SCHEMBL1110561 | 0.79 | KCNA5 (0.50) | KCNA5ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1319869 | 0.79 | ACLY (0.45) | ACLY | |
| SCHEMBL1318818 | 0.79 | ALDH1A1 (0.56) | KCNA5ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1319724 | 0.79 | KCNA5 (0.65) | KCNA5ACLYMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | KCNA5 2527/4885ALDH1A1 49/4885KDM4E 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.